Suzhou’s CStone Pharma has been approved to start an Australian Phase I clinical trial of its CDK4/6 inhibitor as a treatment for solid tumor cancers. CS3002 is a selective inhibitor of the cyclin-dependent kinases 4 and 6 (CDK4/6), a mechanism that is thought to induce the cell cycle arrest of tumor cells. CStone said preclinical tests have shown CS3002 to have potential efficacy in combination with endocrine therapy or immune checkpoint inhibitor therapies. The company expects to start a Phase I trial of the candidate in China before the end of 2019. Source: China Biotoday
